Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Kancera, Novakand, Orgenesis, Recardio, Virpax.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Avacta, Atyr, Biocon, Eli Lilly, Sun, Torqur.
There have been plenty of multi-billion-dollar mega mergers in the past few years but most have fallen short of their goals. In the latest edition of the BioWorld Insider podcast, Karen Carey, BioWorld’s senior managing editor and chief analyst, unpacked the details in 21 of the biggest M&As and found very few have turned out to be good deals for the buyer.
The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing losses to under 4% by June, before experiencing a sharp downturn in the second half of the year.
The disclosure of a new candidate by Dewpoint Therapeutics Inc. was the latest in the percolating beta-catenin/Wnt space, where a handful of firms have been making progress.
RSS
